Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dr. Reddy's Laboratories Limited (RDY) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Dr. Reddy's files reports such as Form 6-K with the Securities and Exchange Commission, providing investors with access to financial results, board and corporate actions, and other information furnished under its home-country requirements.
Key filing types for Dr. Reddy's include periodic Form 6-K submissions that often attach consolidated IFRS financial statements, segment data for Global Generics and Pharmaceutical Services and Active Ingredients (PSAI), and management commentary on revenue trends, R&D spending and regional performance. These filings can also include intimations regarding board meetings, corporate actions and other material updates first disclosed in India.
For a pharmaceutical manufacturer active in APIs, generics, branded generics, biosimilars and OTC products, SEC filings are a primary source for understanding segment performance, geographic mix and investment in R&D. Investors can use them to track how Dr. Reddy's generics and biosimilars portfolios evolve, how collaborations and acquisitions contribute to results, and how the company allocates capital across regions and product categories.
On Stock Titan, each new RDY filing from EDGAR is captured and organized chronologically. AI-powered summaries help explain the main points of lengthy documents, highlighting items such as revenue movements, margin changes, R&D focus areas and notable regulatory or ESG disclosures. Users can quickly scan these summaries before diving into the full text of a 6-K or related exhibits.
In addition to financial information, this page can surface filings that relate to governance, risk and compliance, complementing press releases about inspections, recalls or ESG recognitions. Together, these documents provide a structured view of Dr. Reddy's regulatory footprint in the U.S. and support deeper analysis of the RDY stock for research-oriented investors.
DR REDDYS LABORATORIES LTD director Kodumudi Pranatharthi Haran Krishnan has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his official status as a director and sets the baseline record of his holdings for future Form 4 or Form 5 updates.
DR REDDYS LABORATORIES LTD director Leo Puri has filed an initial insider ownership report on Form 3. This filing establishes his status as a reporting insider of the company but does not list any specific transactions, focusing instead on baseline disclosure and compliance with insider reporting rules.
DR REDDYS LABORATORIES LTD director Arun Madhavan Kumar filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing does not list any transactions or holdings and simply establishes his status as a reporting person for future ownership disclosures.
Dr. Reddy’s Laboratories Limited has allotted 3,675 equity shares of Re.1 each on March 26, 2026 to eligible employees who exercised stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. These equity shares rank pari passu with the company’s existing shares, and total issued shares after this allotment are stated as 83,46,57,970, with a corresponding issued share capital of Rs. 83,46,57,970.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to inform investors that its Board has approved an amended Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information under India’s SEBI insider trading rules.
The code designates the Head of Investor Relations as Chief Investor Relations Officer, responsible for prompt, uniform disclosure of any unpublished price sensitive information to all stock exchanges and on the company website, and for quickly correcting any inadvertent selective disclosure. It restricts use of such information to a strict “need to know” basis, explicitly bars sharing it via social media, and allows sharing only for legitimate purposes with partners and advisors who are then treated as insiders.
The company will maintain a structured digital database of who shares and receives unpublished price sensitive information, including identifiers such as PAN, for at least eight years and longer if required for SEBI proceedings. The Board will review and update the code to align with future changes in SEBI regulations and listing requirements.
Dr. Reddy’s Laboratories Limited has scheduled a Board of Directors meeting for May 12, 2026 to consider the audited standalone and consolidated financial results for the quarter and financial year ending March 31, 2026.
The company also announced that, under SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in its securities will be closed from March 25, 2026 to May 14, 2026, both days inclusive.
Dr. Reddy’s Laboratories has launched Obeda®, India’s first Drugs Controller General of India (DCGI)‑approved generic semaglutide injection for managing type 2 diabetes. The product marks a Day‑1 entry after patent expiry and targets a country with more than 101 million adults living with diabetes.
Obeda® is available in 2 mg and 4 mg pre‑filled disposable pens for once‑weekly subcutaneous use, with each pen delivering at least four weekly doses at a cost of INR 4,200 per month. A Phase III trial in 312 participants showed non‑inferior efficacy and safety versus the innovator, and Dr. Reddy’s is pairing the launch with the SemaKare™ patient‑support program and plans for broader GLP‑1 portfolios and metabolic centres of excellence in India.
DR REDDYS LABORATORIES LTD director Satish K Reddy reports his existing equity ownership in a Form 3. He holds 10,107,505 equity shares directly. Indirectly, he is shown with 27,618,385 equity shares via Kallam Satish Reddy HUF and 75,630,620 equity shares via the VSD Family Trust as trustee. This filing records holdings and does not show any new buying or selling activity.
DR REDDYS LABORATORIES LTD director G V Prasad has filed an initial insider ownership report showing indirect holdings of the company’s equity shares. The filing lists 12,717,090 equity shares held through “Gunupati Venkateswara Prasad HUF” and 96,095,920 equity shares held through the “GVP Family Trust (as a Trustee)”. These are reported as indirect positions rather than personal direct holdings and do not reflect any new buy or sell transactions.
Dr. Reddy’s Laboratories Limited has received three orders from the GST Authority covering FY 2019-20 to FY 2021-22, raising tax demands with interest and penalties on the ground that certain supplies are taxable in nature.
The penalties total ₹2,19,48,944 for FY 2019-20, ₹50,406 for FY 2020-21, and ₹4,384 for FY 2021-22. The company states that, based on its evaluation, these orders have no material impact on its financials, operations, or other activities and it will evaluate filing an appeal with the appellate authority.